COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,676 Articles (22,913 medRxiv, 8,763 bioRxiv)

Most recent first Previous |  Page 1291: Articles 12901-12910  | Next

Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization using a versatile adenovirus-inspired multimerization platform
Chevillard, C., Amen, A., Besson, S., Hannani, D., Bally, I., Dettling, V., Gout, E., Moreau, C. J., Buisson, M., Gallet, S., Fenel, D., Vassal-Stermann, E., Schoehn, G., Poignard, P., Dagher, M.-C., Fender, P.
10.1101/2021.09.13.460076 — Posted: 2021-09-13
The key features of SARS-CoV-2 leader and NSP1 required for viral escape of NSP1-mediated repression
Bujanic, L., Shevchuk, O., von Kuegelgen, N., Ludwik, K., Koppstein, D., Zerna, N., Sickmann, A., Chekulaeva, M.
10.1101/2021.09.13.460054 — Posted: 2021-09-13
Rehabilitation in Survivors of COVID-19 (RE2SCUE): a nonrandomized, controlled, and open protocol
Campos, M. C., Nery, T., Alves, A. C. d. B., Speck, A. E., Vieira, D. S. R., Schneider, I. J. C., Matos, M. P. P., Arcencio, L., Aguiar, A. S.
10.1101/2021.09.06.21262986 — Posted: 2021-09-13
Ultrafast, one-step, and microwave heating-based synthesis of DNA/RNA-AuNP conjugates
Huang, M., Xiong, E., Hu, M., Yue, H., Tian, T., Zhu, D., Zhou, X.
10.1101/2021.09.11.459879 — Posted: 2021-09-13
Structure-activity relationships of B.1.617 and other SARS-CoV-2 spike variants
Yang, T.-J., Yu, P.-Y., Chang, Y.-C., Chang, N.-E., Tsai, Y.-X., Liang, K.-H., Draczkowski, P., Lin, B., Wang, Y.-S., Chien, Y.-C., Khoo, K.-H., Wu, H.-C., Hsu, S.-T. D.
10.1101/2021.09.12.459978 — Posted: 2021-09-13 Discussion: Onsite
Real-time monitoring and analysis of SARS-CoV-2 nanopore sequencing with minoTour.
Munro, R. J., Holmes, N., Moore, C., Carlile, M., Payne, A., Loose, M. W.
10.1101/2021.09.13.459777 — Posted: 2021-09-13
Elucidation of the interactions between SARS-CoV-2 Spike protein and wild and mutant types of IFITM proteins by in silico methods
Giritlioglu, N. I., Koprululu Kucuk, G.
10.1101/2021.09.13.460130 — Posted: 2021-09-13
Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.
Schafer, A., Martinez, D. R., Won, J. J., Moreira, F. R., Brown, A. J., Gully, K. L., Kalla, R., Chun, K., Du Pont, V., Babusis, D., Tang, J., Murakami, E., Subramanian, R., Barrett, K. T., Bleier, B. J., Bannister, R., Feng, J. Y., Bilello, J. P., Cihlar, T., Mackman, R. L., Montgomery, S. A., Baric, R. S., Sheahan, T. P.
10.1101/2021.09.13.460111 — Posted: 2021-09-13
The clinically extremely vulnerable to COVID: Identification and changes in health care while self-isolating (shielding) during the coronavirus pandemic
Butler, J. E., Nath, M., Blana, D., Ball, W. P., Beech, N., Black, C., Osler, G., Peytrignet, S., Wilde, K., Wozniak, A., Sawhney, S.
10.1101/2021.09.09.21263026 — Posted: 2021-09-13
Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent?
Sharma, N., Sharma, P., Basu, S., Bakshi, R., Gupta, E., Agarwal, R., Dushyant, K., Mundeja, N., Marak, Z., Singh, S., Singh, G., Rustagi, R., Sarin, S. K.
10.1101/2021.09.09.21263331 — Posted: 2021-09-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).